{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.48","value":"4.6"},{"groupId":"OG001","spread":"7.76","value":"-2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"The EQ visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled \"The best health you can imagine\" and \"The worst health you can imagine.\" Responses are marked on a 0-100 scale with higher scores indicating higher health-related quality of life (i.e., better outcome).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with the treatment group designated according to the randomization. Overall number analyzed is the number of participants available for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 3 Day 1","title":"Change From Baseline in EQ-5D-5L Visual Analogue Scale (EQ-5D-5L VAS) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}